NeoGenomics Advances AI-Driven Oncology Insights at AACR
Fort Myers, Florida | April 13, 2026 NeoGenomics, Inc. has announced the presentation of multiple scientific abstracts at the...
MRD
Advertisement
Natera Strengthens MRD Leadership With Acquisition of Foresight Diagnostics
AUSTIN, Texas — December 5, 2025 — Natera has announced the acquisition of Foresight Diagnostics, a precision oncology company...
Bristol Myers Squibb’s Iberdomide Shows Strong Phase 3 Results in Multiple Myeloma
Princeton, N.J., September 22, 2025 – Bristol Myers Squibb (BMS) announced that its investigational cereblon E3 ligase modulator (CELMoD™)...
Foresight Diagnostics Demonstrates Ultrasensitive MRD Detection in Early-Stage Lung Cancer at IASLC 2025
Foresight Diagnostics, a leader in ultrasensitive minimal residual disease (MRD) detection, presented new clinical performance data on its Foresight...
Advertisement
